Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity are known and used, they often fail to achieve satisfactory long-term patient outcomes and survival. Recently...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1479483/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553876021411840 |
|---|---|
| author | Marketa Skalickova Marketa Skalickova Katerina Hadrava Vanova Ondrej Uher Jindriska Leischner Fialova Jindriska Leischner Fialova Jindriska Leischner Fialova Katerina Petrlakova Michal Masarik Michal Masarik Michal Masarik Michal Masarik Zdeněk Kejík Zdeněk Kejík Pavel Martasek Karel Pacak Milan Jakubek Milan Jakubek |
| author_facet | Marketa Skalickova Marketa Skalickova Katerina Hadrava Vanova Ondrej Uher Jindriska Leischner Fialova Jindriska Leischner Fialova Jindriska Leischner Fialova Katerina Petrlakova Michal Masarik Michal Masarik Michal Masarik Michal Masarik Zdeněk Kejík Zdeněk Kejík Pavel Martasek Karel Pacak Milan Jakubek Milan Jakubek |
| author_sort | Marketa Skalickova |
| collection | DOAJ |
| description | Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity are known and used, they often fail to achieve satisfactory long-term patient outcomes and survival. Recently, immunotherapy has shown success in patients by harnessing important interactions between the immune system and cancer. However, many of these therapies lead to frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, in severe cases, fatalities. New therapeutic approaches like intratumoral immunotherapy, characterized by reduced side effects, cost, and systemic toxicity, offer promising prospects for future applications in clinical oncology. In the context of locally advanced or metastatic cancer, combining diverse immunotherapeutic and other treatment strategies targeting multiple cancer hallmarks appears crucial. Such combination therapies hold promise for improving patient outcomes and survival and for promoting a sustained systemic response. This review aims to provide a current overview of immunotherapeutic approaches, specifically focusing on the intratumoral administration of drugs in patients with locally advanced and metastatic cancers. It also explores the integration of intratumoral administration with other modalities to maximize therapeutic response. Additionally, the review summarizes recent advances in intratumoral immunotherapy and discusses novel therapeutic approaches, outlining future directions in the field. |
| format | Article |
| id | doaj-art-2fced3d048c44c9ab0552b00dd7080a7 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2fced3d048c44c9ab0552b00dd7080a72025-01-09T06:10:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14794831479483Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancerMarketa Skalickova0Marketa Skalickova1Katerina Hadrava Vanova2Ondrej Uher3Jindriska Leischner Fialova4Jindriska Leischner Fialova5Jindriska Leischner Fialova6Katerina Petrlakova7Michal Masarik8Michal Masarik9Michal Masarik10Michal Masarik11Zdeněk Kejík12Zdeněk Kejík13Pavel Martasek14Karel Pacak15Milan Jakubek16Milan Jakubek17BIOCEV, First Faculty of Medicine, Charles University, Vestec, CzechiaDepartment of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, CzechiaSection on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United StatesSection on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United StatesBIOCEV, First Faculty of Medicine, Charles University, Vestec, CzechiaDepartment of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, CzechiaDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, CzechiaBIOCEV, First Faculty of Medicine, Charles University, Vestec, CzechiaDepartment of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, CzechiaDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Physiology, Faculty of Medicine, Masaryk University, Brno, CzechiaBIOCEV, First Faculty of Medicine, Charles University, Vestec, CzechiaDepartment of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, CzechiaDepartment of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, CzechiaSection on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United StatesBIOCEV, First Faculty of Medicine, Charles University, Vestec, CzechiaDepartment of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, CzechiaDespite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity are known and used, they often fail to achieve satisfactory long-term patient outcomes and survival. Recently, immunotherapy has shown success in patients by harnessing important interactions between the immune system and cancer. However, many of these therapies lead to frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, in severe cases, fatalities. New therapeutic approaches like intratumoral immunotherapy, characterized by reduced side effects, cost, and systemic toxicity, offer promising prospects for future applications in clinical oncology. In the context of locally advanced or metastatic cancer, combining diverse immunotherapeutic and other treatment strategies targeting multiple cancer hallmarks appears crucial. Such combination therapies hold promise for improving patient outcomes and survival and for promoting a sustained systemic response. This review aims to provide a current overview of immunotherapeutic approaches, specifically focusing on the intratumoral administration of drugs in patients with locally advanced and metastatic cancers. It also explores the integration of intratumoral administration with other modalities to maximize therapeutic response. Additionally, the review summarizes recent advances in intratumoral immunotherapy and discusses novel therapeutic approaches, outlining future directions in the field.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1479483/fullcancerimmunotherapyintratumoralcombination therapyadvanced and metastatic cancer |
| spellingShingle | Marketa Skalickova Marketa Skalickova Katerina Hadrava Vanova Ondrej Uher Jindriska Leischner Fialova Jindriska Leischner Fialova Jindriska Leischner Fialova Katerina Petrlakova Michal Masarik Michal Masarik Michal Masarik Michal Masarik Zdeněk Kejík Zdeněk Kejík Pavel Martasek Karel Pacak Milan Jakubek Milan Jakubek Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer Frontiers in Immunology cancer immunotherapy intratumoral combination therapy advanced and metastatic cancer |
| title | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer |
| title_full | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer |
| title_fullStr | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer |
| title_full_unstemmed | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer |
| title_short | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer |
| title_sort | injecting hope the potential of intratumoral immunotherapy for locally advanced and metastatic cancer |
| topic | cancer immunotherapy intratumoral combination therapy advanced and metastatic cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1479483/full |
| work_keys_str_mv | AT marketaskalickova injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT marketaskalickova injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT katerinahadravavanova injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT ondrejuher injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT jindriskaleischnerfialova injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT jindriskaleischnerfialova injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT jindriskaleischnerfialova injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT katerinapetrlakova injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT michalmasarik injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT michalmasarik injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT michalmasarik injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT michalmasarik injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT zdenekkejik injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT zdenekkejik injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT pavelmartasek injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT karelpacak injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT milanjakubek injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer AT milanjakubek injectinghopethepotentialofintratumoralimmunotherapyforlocallyadvancedandmetastaticcancer |